ERYTHRODERMA AND ANTITUBERCULOUS THERAPY: CLINICAL CASE


Cite item

Full Text

Abstract

Erythroderma represents one of the most complex problems of dermatology. First of all, it is explained by variety of reasons, a pathogenesis ambiguity, monotonous clinical picture, tendency of many forms of an erythroderma to a long and heavy current and resistance to therapy. The erythroderma doesn’t represent a certain disease, it is, most likely, clinical implication of set of various diseases. The majority of erythroderma cases described in literature have been induced by different types of medicines and dietary supplements. In English-speaking literature more than ten cases of erythroderma induced from various components of anti-tuberculous therapy are described. The first case of eryhtroderma in Russian-speaking scientific literature which appeared in five months from the beginning of anti-tuberculous therapy is presented.

About the authors

Denis V. Zaslavsky

St.Petersburg State Pediatric Medical University

MD, PhD, DSc, St.Petersburg State Pediatric Medical Univercity, St.Petersburg, 194100, Russian Federation St.Petersburg, 194100, Russian Federation

S. S Yakushenko

Lipetsk Regional Skin and Venereal Diseases clinic

Lipetsk, 398000, Russian Federation

M. A Koroleva

Lipetsk Regional Antitubercular Clinic

Lipetsk, 398035, Russian Federation

I. N Chuprov

North-Western State Medical University n.a. I.I. Mechnikov

St.Petersburg, 191015, Russian Federation

A. A Sidikov

St.Petersburg State Pediatric Medical University

St.Petersburg, 194100, Russian Federation

References

  1. Заславский Д.В., Раводин Р.А., Татарская О.Б., Сыдиков А.А., Хведелидзе М. Г. Эритродермия: современные вопросы диагностики и лечения. Педиатр. 2014; 1: 97-103.
  2. Голдсмит Л.А., Кац С.И., Джилкрест Б.А., Паллер Э.С., Леффель Д.Дж., Вольф К. Дерматология Фицпатрика в клинической практике. Пер. с англ. 2-е изд. В 3 т. М.: БИНОМ: Из-во Панфилова; 2015. т. 1.
  3. Burns T., Breathnach S., Cox N., Griffiths Ch. Rook’s textbook of dermatology. 8 ed. Oxford: Willey-Blackwell; 2010: 4432-3
  4. Олисова О.Ю., Теплюк Н.П., Плиева Л.Р., Ломоносов К.М. Эритродермическая форма болезни Девержи. Российский журнал кожных и венерических болезней. 2014; 17(1): 18-20
  5. King L.E., Dufresne R.G., Lovett G.L., Rosin M.A. Erythroderma: review of 82 cases. South. Med. J. 1986; 79(10): 1210-5.
  6. Hasan T., Jansen C.T. Erythroderma: A follow-up of fifty cases. J. Am. Acad. Dermatol. 1983; 8(6): 836-40.
  7. Freedberg I.M. Exfoliative dermatitis. In: Freedberg I.M., Eisen A.Z., Wolff K., Austen K.F., Goldsmith L.A., Katz S.I., Fitzpatrick T.B., eds. Fitzpatrick’s Dermatology in General Medicine. 5th ed. New York: McGraw-Hill; 1999: 534-5.
  8. Cox N.H., Gordon P.M., Dodd H. Generalized pustular and erythrodermic psoriasis associated with bupropion treatment. Br. J. Dermatol. 2002; 146(6): 1061-3.
  9. Guin J.D., Philips D. Erythroderma from systemic contact dermatitis: a complications of systemic gentamicin in a patients with contact allergy to neomycin. Cutis. 1989; 43(6): 564-7.
  10. Patki A.H., Menta J.M. Dapsone - induced erythroderma with Beau’s lines. Lepr. Rev. 1989; 60(4): 274-7.
  11. Wittal R.A., Ficher G.O., Georgouras K.E., Baird P.J. Skin reactions to diltiazem. Austral. J. Dermatol. 1992; 33(1): 11-8.
  12. Batinac T., Zamolo G., Jonjic N., Gruber F., Nacinovic A., Seili-Bekafigo I., et al. Angioimmunobalstic lymphadenopathy with dysproteinemia following doxycycline administration. Tumori. 2003; 89(1): 91-5.
  13. Rosin M.A., King L.E.Jr. Isoniazid-induced exfoliative dermatitis. South. Med. J. 1982; 75(1): 81.
  14. Rietsema W.J. Fever, erythroderma, abdominal pain, and renal failure following initiation of indinavir therapy. Clin. Infect. Dis. 1997; 25(5): 1268-9.
  15. Sigurdsson V., Steegmans H.A., Vloten W.A. The incidence of erythroderma: A survey among all dermatologists in The Netherlands. J. Am. Acad. Dermatol. 2001; 45(5): 675-8.
  16. Botella-Estrada R., Sammartin O., Oliver V., Febrer I., Aliaga A. Ertyhroderma: a clinicopathologic study of 56 cases. Arch. Dermatol. 1994; 130(12): 1503-7.
  17. Polyzos A., Tsavaris N., Kosmas C., Arnaouti T., Kalahanis N., Tsigris C., et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-years experience. Oncology. 2001; 61(2): 129-33.
  18. Pajus I., Lestang P., Liote F., Dryll A. Erythroderma after clodronate treatment. BMJ. 1993; 307(6902): 484.
  19. Pavithran K. Exfoliative dermatitis after clofazimine. Int. J. Lepr. Other Mycobact. Dis. 1985; 53(4): 645-6.
  20. Nicolis G.D., Helwig E.B. Exfoliative dermatitis: a clinico-pathologic study of 135 cases. Arch. Dermatol. 1973; 108(6): 788-97.
  21. Kuhnley E.J., Granoff A.L. Exfoliative dermatitis during lithium treatment. Am. J. Psychiatry. 1979; 136(10): 1340-1.
  22. Reynolds N.J., Jones S.K., Crossley K., Harman R.R. Exfoliative dermatitisdue to nifedipine. Br. J. Dermatol.1989; 121(3): 401-4.
  23. Rebuck J.A., Rybak M.J., Ramos D.P., Weingarten C.M. Omeprazole-induced exfoliative dermatitis. Pharmacotherapy. 1998; 18(4): 877-9.
  24. Slagel G.A., James W.D. Plaquenil-induced erythroderma. J. Am. Acad. Dermatol. 1985; 12(5): 857-62.
  25. Sigurdsson V., Toonstra J., Hezemans-Boer M., van Vloten W.A. Erythroderma: a clinical and follow-up study of 102 patients, with special emphasis on survival. J. Am. Acad. Dermatol. 1996; 35(1): 53-7.
  26. Gonzalo-Garijo M.A., Perez-Calderon R., de Argila D., Rodriguez-Nevado I. Erythroderma to pseudoephedrine in a patients with contact allergy to phenylephrine. Allergol. Immunopathol. 2002; 30(4): 239-42.
  27. Wantzin G.L., Thomsen K. A new cutaneous side effects of isotretinoin. J. Am. Acad. Dermatol. 1985; 13(4): 665.
  28. Goldin H.M., Schweitzer W.J., Bronson D.M. Rifampin and exfoliative dermatitis. Ann. Internal. Med. 1987; 107(5): 789.
  29. Sehgal V.N., Srivastava G. Exfoliative dermatitis. A prospective study of 80 patients. Dermatologica. 1986; 173(6): 278-84.
  30. Hall V.C., El-Azhary R.A., Bouwhuis S., Rajkumar S.V. Dermatologic side effects of thalidomide in patients with multiple myeloma. J. Am. Acad. Dermatol. 2003; 48(4): 548-52.
  31. Asnis L.A., Gaspari A.A. Cutaneous reactions to recombinant cytokine therapy. J. Am. Acad. Dermatol. 1995; 33(3): 393-410.
  32. Sparsa A., Bedane C., Benazahary H., De Vencay P., Gauthier M.L., Le Brun V., et al. Drug-induced hypersentivity syndrome due to fluindione. Ann. Dermatol. Venereol. 2001; 128(1): 1014-8.
  33. D’Incan M., Souteyrand P., Bignon Y.J., Fonck Y., Roger H. Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sezary syndrome. Arch. Dermatol. 1992; 128(10): 1371-4.
  34. Yantis P.L., Bridges M.E., Pittman F.E. Cimetidine-induced exfoliative dermatitis. Dig. Dis. Sci. 1980; 25(1): 73-4.
  35. Lee T.C., Hook C.C., Long H.J. Severe exfoliative dermatitis associated with hand ischemia during cisplatin therapy. Mayo Clin. Proc. 1994; 69(1): 80-2.
  36. Catlin D.H., Sekera M., Adelman Dc. Erythroderma associated with ingestion of an herbal product. West. J. Med. 1993; 159(4): 491-3.
  37. Ahearn G.S., Selim M.A., Tapson V.F. Severe erythroderma as a complications of continuous epoprestenol therapy. Chest. 2002; 122(1): 378-80.
  38. Cuxart M., Just M., Sans R. Generalized exfoliative dermatitis caused by erythropoietin. Med. Clin. 2000; 115(4): 158.
  39. Miranda M.F., Rege V.L., Coelho V.E. Exfoliative dermatitis due to ethambutol. Indian J. Tuberculosis. 1996; 43(1): 103-4.
  40. Tan W.C., Ong C.K., Kang S.C., Razak M.A. Two years a review of cutaneous adverse drug reaction from first line anti-tuberculous drugs. Med. J. Malaysia. 2007; 62(2): 143-6.
  41. Dua R., Sindhwani G., Rawat J. Exfoliative dermatitis to all four first line oral anti-tubercular drugs. Indian J. Tuberc. 2010; 57(1): 53-6.
  42. Родин Ю.А. Гистологическая реакция замедленного типа при вторичных эритродермиях. Вестник дерматологии и венерологии. 1969; 8: 16-9
  43. Sigurdsson V., de Vries I.J., Toonstra J., Bihari I.C., Thepen T., Bruijnzeel-Koomen C.A., et al. Expression of VCAM-1, ICAM-1, E-selectin, and P-selectin on endothelium in situ in patients with erythroderma, mycosis fungoides and atopic dermatitis. J. Cutan. Pathol. 2000; 27(9): 436-40
  44. Родионов А.Н. Эритродермическая лимфома кожи. Л.: ВМедЛ; 1989
  45. Chan Y.C., Yosipovitch G. Erythroderma: an unusual presentation of pulmonary tuberculosis. Br. J. Dermatol. 2003; 148(2): 346-8.
  46. Kishore P.V., Palaian S., Prabhu S., Prabhu M., Mishra P. Drug induced maculopapular rash with the commonly used first line antitubercular drug, pyrazinamide. Inter. J. Dermatol. 2007; 5(1): 42-4.
  47. Khayyam K.U., Imam F., Sharma M., Pillai K.K., Behera D. Pyrazinamide-induced maculopapular rash. Indian J. Dermatol. 2010; 55(4): 384-6.
  48. Perdu D., Lavaud F., Prґevost A., Deschamps F., Cambie M.P., Bongrain E., et al. Erythema multiforme due to pyrazinamide. Allergy.1996; 51(5): 340-2.
  49. Naziha K., Maha B.S., Dorsaf M., Mohsen H. DRESS syndrome caused by pyrazinamide. Egyptian Dermatol. Online J. 2010; 6(2): 9-12.

Copyright (c) 2017 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies